A Case-Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection.

Autor: Bortul M; Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy.; Breast Unit, Azienda Sanitaria Universitaria Integrata Giuliano Isontina (ASUGI), 34149 Trieste, Italy., Giudici F; Cancer Epidemiologic Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 33081 Aviano, Italy., Tierno D; Department of Life Sciences, University of Trieste, 34127 Trieste, Italy., Generali D; Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy.; Breast Cancer Unit and Translational Research Unit, Azienda Socio-Sanitaria Territoriale di Cremona-ASST, 26100 Cremona, Italy., Scomersi S; Breast Unit, Azienda Sanitaria Universitaria Integrata Giuliano Isontina (ASUGI), 34149 Trieste, Italy., Grassi G; Department of Life Sciences, University of Trieste, 34127 Trieste, Italy., Bottin C; Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy., Cappelletti MR; Breast Cancer Unit and Translational Research Unit, Azienda Socio-Sanitaria Territoriale di Cremona-ASST, 26100 Cremona, Italy., Zanconati F; Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy.; Breast Unit, Azienda Sanitaria Universitaria Integrata Giuliano Isontina (ASUGI), 34149 Trieste, Italy., Scaggiante B; Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2023 May 10; Vol. 24 (10). Date of Electronic Publication: 2023 May 10.
DOI: 10.3390/ijms24108520
Abstrakt: Background: In Western countries, breast cancer (BC) is the most common cancer in women. Early detection has a positive impact on survival, quality of life, and public health costs. Mammography screening programs have increased early detection rates, but new approaches to more personalized surveillance could further improve diagnosis. Circulating cell-free DNA (cfDNA) in blood could provide a potential tool for early diagnosis by analyzing cfDNA quantity, circulating tumor DNA mutations, or cfDNA integrity (cfDI).
Methods: Plasma was obtained from the blood of 106 breast cancer patients (cases) and 103 healthy women (controls). Digital droplet PCR was used for the determination of ALU 260/111 bp and LINE-1 266/97 bp copy number ratio and cfDI. cfDNA abundance was calculated using copies of the EEF1A2 gene. The accuracy of biomarker discrimination was analyzed with receiver operating characteristic curve (ROC). Sensitivity analyses were performed to account for age as a potential confounder.
Results: Cases had significantly lower ALU 260/111 or LINE-1 266/97 copy number ratios (median; ALU 260/111 = 0.08, LINE-1 266/97 = 0.20), compared with control (median; ALU 260/111 = 0.10, LINE-1 266/97 = 0.28) ( p < 0.001). ROC analysis showed that copy number ratio discriminated cases from controls (area under the curve, AUC = 0.69, 95% CI: 0.62-0.76 for ALU and 0.80, 95% CI: 0.73-0.86 for LINE-1). ROC from cfDI confirmed the better diagnostic performance of LINE-1 compared with ALU.
Conclusions: Analysis of LINE-1 266/97 copy number ratio or cfDI by ddPCR appears to be a useful noninvasive test that could aid in early BC detection. Further studies in a large cohort are needed to validate the biomarker.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje